drugset / Trial / NCT05861674
A Study to Assess Efficacy and Safety of HH-003 Injection in Subjects With Chronic Hepatitis Delta Virus Infection
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, randomized, controlled, open-label, Phase IIb study of HH-003 injection, HH-003 injection is a monoclonal antibody targeting Hepatitis B virus. This study aims to assess efficacy and safety in subjects with chronic hepatitis delta virus infection.
Timeline
- Start
- 2023-06-16
- Primary completion
- 2024-07-18
- Completion
- 2025-06-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Libevitug | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Libevitug | Monoclonal antibody | 20 mg/kg | Intravenous |
| Background | TAF | Unknown | 25 mg | Oral |